



OPEN

Competition between electrostatic interactions and halogen bonding in the protein–ligand system: structural and thermodynamic studies of 5,6-dibromobenzotriazole-hCK2 α complexes

Maria Winiewska-Szajewska^{1,2✉}, Honorata Czapinska^{1,3}, Magdalena Kaus-Drobek¹, Anna Fricke^{1,3}, Kinga Mieczkowska¹, Michał Dadlez¹, Matthias Bochtler^{1,3} & Jarosław Poznański^{1✉}

CK2 is a member of the CMGC group of eukaryotic protein kinases and a cancer drug target. It can be efficiently inhibited by halogenated benzotriazoles and benzimidazoles. Depending on the scaffold, substitution pattern, and pH, these compounds are either neutral or anionic. Their binding poses are dictated by a hydrophobic effect (desolvation) and a tug of war between a salt bridge/hydrogen bond (to K68) and halogen bonding (to E114 and V116 backbone oxygens). Here, we test the idea that binding poses might be controllable by pH for ligands with near-neutral pK_a , using the conditionally anionic 5,6-DBBt and constitutively anionic TBBt as our models. We characterize the binding by low-volume Differential Scanning Fluorimetry (nanoDSF), Isothermal Calorimetry (ITC), Hydrogen/Deuterium eXchange (HDX), and X-ray crystallography (MX). The data indicate that the ligand pose away from the hinge dominates for the entire tested pH range (5.5–8.5). The insensitivity of the binding mode to pH is attributed to the perturbation of ligand pK_a upon binding that keeps it anionic in the ligand binding pocket at all tested pH values. However, a minor population of the ligand, detectable only by HDX, shifts towards the hinge in acidic conditions. Our findings demonstrate that electrostatic (ionic) interactions predominate over halogen bonding.

Abbreviations

hCK2 α	Alpha subunit of human casein kinase CK2
TBBt	Tetrabromobenzotriazole
5,6-DBBt	5,6-Dibromobenzotriazole
TBBi	Tetrabromobenzimidazole
nanoDSF	Low volume differential scanning fluorimetry
ITC	Isothermal titration calorimetry
HDX	Hydrogen–deuterium exchange
MS	Mass spectrometry
MX	Macromolecular X-ray crystallography
DRB	5,6-Dichloro-1- β -D-ribofuranosylbenzimidazole
DBU	1,8-Diazabicyclo[5,4,0]undec-7-ene

¹Institute of Biochemistry and Biophysics PAS, Pawinskiego 5a, 02-106 Warsaw, Poland. ²Division of Biophysics, Institute of Experimental Physics, University of Warsaw, Pasteura 5, 02-089 Warsaw, Poland. ³International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland. ✉email: mwin@ibb.waw.pl; jarek@ibb.waw.pl

Protein kinase CK2 is a highly conserved serine/threonine kinase from the CMGC group¹. The enzyme is ubiquitously expressed in a broad spectrum of eukaryotic cells. Unlike most other protein kinases, CK2 is constitutively active^{2,3}. The holoenzyme exists in vivo as a heterotetramer consisting of two catalytic α - and/or α' -subunits and two regulatory β -subunits⁴. In vitro, the catalytic domain is also active as a monomeric kinase³. Among catalytic subunits of the holoenzyme, the α subunit has the primary role and is vital in mammalian development⁵. By contrast, the α' -subunit appears to be necessary only for spermatogenesis⁶. CK2 phosphorylates a diverse range of substrate proteins with serine/threonine residues in acidic regions⁷. Over 300 substrates were known in 2003⁸, and more have been discovered since. Because of the diversity of CK2 substrates, the enzyme plays a role in many medical conditions^{9,10}, particularly carcinomas^{11–15}. The emerging role of CK2 as an attractive cancer target has triggered the development of inhibitors. At least two of them have qualified for phase II clinical trials: CIGB-300^{16–20} and CX-4945^{21–23}. Recently, inhibition of CK2 was also identified as a potential COVID-19 treatment^{24,25}. CX-4945 is already in trials in this regard (<https://clinicaltrials.gov/ct2/show/NCT04668209>).

Many CK2 inhibitors are halogenated, including DRB²⁶, brominated and iodinated benzimidazole derivatives^{27–29}, and halogenated benzotriazoles^{30–33}. The promising properties of halogenated benzotriazoles have prompted extensive investigations of the entire series of such inhibitors^{34,35}. Halogenation alters molecular properties in several ways. It makes compounds more hydrophobic, lowers the pK_a of ionizable groups, and creates opportunities for halogen bonding. Halogen bonding is the favorable interaction between a halogen atom (Cl, Br, I) as the X-bond donor, and an electron-donating group as the X-bond acceptor. Halogen bonding is evidenced in structural databases by unexpectedly short interatomic contacts. Its topology is well described in protein–ligand systems: the backbone carbonyl oxygen atoms are the most abundant X-bond acceptors³⁶, pi-electron systems of the peptide bond³⁷ or an aromatic ring³⁸ are less frequent, and sidechain oxygen atoms are identified occasionally³⁹. In complexes of protein kinases with halogenated ligands, the most favored X-bond acceptors are backbone carbonyls of two residues located in the hinge region (E114 and V116 in human CK2 α) and the aromatic ring of the preceding residue (F113 in hCK2 α)^{39,40}. The X-bond acceptor–halogen distances are shorter than the sum of their VDW radii, and the linear geometry of C–X...Acc system is strongly preferred³⁶. The thermodynamic contribution of a halogen bond is still under debate^{36,41–59}. However, its estimates differ substantially, varying from 0.8⁶⁰ up to 30 kJ/mol³⁶.

Many complexes of CK2 with halogenated compounds have been experimentally characterized. Such complexes are often stabilized by halogen bond(s) between the ligand and the hinge region of the protein kinase³⁹. In the case of the brominated benzimidazoles or benzotriazoles, halogen bonding between ligands and the CK2 hinge comes at a price. Because of the distance between the hinge and lysine 68 (K68) in the ligand-binding pocket, halogen bonding is mutually exclusive with forming a hydrogen bond or salt bridge between the imidazole or triazole part of the ligand and the lysine amino group. The competition between alternative favorable interactions is well illustrated by a comparison of the binding modes of TBBt and its analog TBBi to maize CK2. In these complexes, TBBt chooses the salt bridge with K68⁶¹. By contrast, TBBi forms two halogen bonds with backbone carbonyl oxygen atoms of residues from the hinge region⁶². The competition between interactions with the hinge and K68 may depend on the protonation state of the ligand. A salt bridge to the ligand in its anionic state is expected to be more favorable than a hydrogen bond to the ligand in its neutral state. For titratable ligands with pK_a values not too far from neutral, the outcome of the competition between the hinge and K68 interactions may therefore be pH-dependent.

Here, we report the thermodynamic characterization of the pH-dependent binding of titratable 5,6-DBBt ($pK_a = 6.93^{63}$) to the catalytic subunit of human CK2. As a reference, we analyzed the binding of always anionic TBBt ($pK_a \sim 5^{64}$) and four non-ionizable neutral analogs: 1-CH₃- and 2-CH₃-derivatives of 5,6-DBBt and TBBt. We present structures of hCK2 α in complex with either 5,6-DBBt or TBBt, determined for crystals grown at pH ranging from 5.5 up to 8.5. The structural data are complemented by hydrogen–deuterium exchange experiments performed for hCK2 α in a complex with 5,6-DBBt at two extreme pH values (6.7 and 8.7). Presented results explicitly confirm that the direct electrostatic interactions predominate over a possible contribution of halogen bonding.

Results

pH-dependent binding of “conditionally anionic” 5,6-DBBt and “constitutively anionic” TBBt and their non-dissociable 1- and 2-methyl analogs monitored by low-volume Differential Scanning Fluorimetry (nanoDSF). We have used low-volume fluorescence-monitored thermal denaturation (nanoDSF) to assess the contribution of the electrostatic interactions and the ionization state of the free ligand to the binding affinity of 5,6-DBBt to hCK2 α . We have analyzed the thermal stability of hCK2 α alone and in the presence of tenfold excess of ligands: 5,6-DBBt, its non-dissociable derivatives (1-CH₃-5,6-DBBt, 2-CH₃-5,6-DBBt), anionic TBBt, and its neutral non-dissociable derivatives (1-CH₃-TBBt and 2-CH₃-TBBt). We have previously published the semi-quantitative analysis of hCK2 α binding affinities to variously brominated benzotriazoles^{34,35}, including 5,6-DBBt and TBBt. In this work, we used TBBt ($pK_a = 4.8 \pm 0.4$; 4.78⁶³, 5⁶⁴) as a consistently anionic ligand in the tested pH range and the compounds with a methyl group attached to the triazole ring as ligands that remain neutral under the experimental conditions. This approach allows formal separation of the purely electrostatic contribution resulting from the dissociation of the triazole proton from other effects.

The mid-point temperature of the thermal denaturation of hCK2 α complexes, T_m , is substantially increased relatively to the free enzyme: at pH 8.7 by 7.2 and 9.3 °C for 5,6-DBBt and TBBt, respectively (Table 1, Fig. 1A). According to the Fisher test, at the significance level of 0.05, the changes in ΔT_m in the presence of 5,6-DBBt must be regarded as pH-dependent (Fig. 1B), roughly reflecting the expected change in the protonation equilibrium of the ligand ($pK_a = 6.93^{63}$). An inverse trend of pH-dependent changes observed for TBBt must indicate an

	Free hCK2α	TBBt	1-CH ₃ -TBBt	2-CH ₃ -TBBt	5,6-DBBt	1-CH ₃ -5,6-DBBt	2-CH ₃ -5,6-DBBt
pH	T _m [°C]	ΔT _m [°C]					
6.5	41.70 ± 0.01	9.80 ± 0.04	1.83 ± 0.04	0.02 ± 0.03	6.52 ± 0.09	0.79 ± 0.03	0.03 ± 0.03
6.7	42.38 ± 0.01	9.99 ± 0.03	2.35 ± 0.03	0.44 ± 0.03	6.64 ± 0.04	0.87 ± 0.03	0.21 ± 0.03
7.0	43.65 ± 0.01	9.71 ± 0.02	2.55 ± 0.02	0.42 ± 0.02	6.83 ± 0.03	1.08 ± 0.02	0.58 ± 0.03
7.2	44.94 ± 0.01	9.32 ± 0.03	1.96 ± 0.03	0.32 ± 0.02	6.86 ± 0.04	0.38 ± 0.02	0.20 ± 0.02
7.5	45.44 ± 0.01	9.20 ± 0.02	2.10 ± 0.02	0.29 ± 0.02	7.48 ± 0.05	1.00 ± 0.02	0.26 ± 0.02
7.7	46.11 ± 0.01	9.10 ± 0.03	2.18 ± 0.02	0.56 ± 0.02	7.41 ± 0.03	0.79 ± 0.02	0.41 ± 0.02
8.0	46.33 ± 0.01	8.91 ± 0.03	2.20 ± 0.03	− 0.12 ± 0.02	7.51 ± 0.04	0.75 ± 0.02	− 0.13 ± 0.02
8.2	46.38 ± 0.01	9.23 ± 0.03	1.98 ± 0.03	0.54 ± 0.02	7.95 ± 0.04	0.49 ± 0.02	0.17 ± 0.02
8.5	46.24 ± 0.02	9.16 ± 0.04	2.05 ± 0.03	0.54 ± 0.03	7.63 ± 0.04	0.93 ± 0.02	0.42 ± 0.02
8.7	46.23 ± 0.01	9.28 ± 0.02	1.99 ± 0.02	0.19 ± 0.03	7.41 ± 0.04	0.78 ± 0.02	0.24 ± 0.02

Table 1. Thermal stability of hCK2α in the free form and in the presence of tenfold excess of bromobenzotriazole ligands as assessed by nanoDSF.




Figure 1. pH-dependence of ΔT_m for the complexes of hCK2α with 5,6-DBBt, TBBt, and their non-dissociable analogs determined using nanoDSF. Comparison of all tested compounds (A), results for 5,6-DBBt at a different scale (B).

alternative source of variation in the apparent binding affinity, presumably associated with the ionization of a neighboring histidine (H160, theoretical $pK_a \sim 7$). Its cationic form possibly enhances the binding of the anionic ligand under moderately acidic conditions. This mechanism is supported by the structure of hCK2α with TBBt (PDB 6TLL⁶⁵), in which the imidazole ring of H160 is close to the triazole ring of TBBt, with the shortest distance between multiple locations of these rings of 3.7 Å (Suppl. Fig. S1).

1-CH₃-5,6-DBBt and 1-CH₃-TBBt, the asymmetric non-dissociable derivatives of 5,6-DBBt and TBBt, affect the protein stability much less: their binding increases the melting temperature by 1.8–2.6 °C and 0.4–1.1 °C, respectively (Table 1, Fig. 1A), indicating that the anionic form is highly preferred for both 5,6-DBBt and TBBt. In the published PDB structures (3OFM, 3RPS, 6HMQ, 7AT9) with bigger alkyl substitutions at N1 of TBBt, the steric bulk in this position does not significantly perturb the interaction with the ATP-binding site of human protein kinase CK2α/CK2α^{66–68}. This, together with modeling (Suppl. Fig. S2A,B), confirms that possible steric effects are negligible. However, methylation at N1 makes the benzotriazole derivatives neutral, which interferes with ligand interaction with K68 and possibly affects the water network at the binding site. Thus, it must be concluded that, at least in the studied system, direct electrostatic interactions predominate over other types of interactions, including putative halogen bonding.

At the significance level of 0.05, the ligand-induced changes in ΔT_m remain pH-independent for the two neutral ligands, but small perturbations at lower pH observed for 1-CH₃-TBBt reproduce the trend identified for

pH	ΔG [kJ·mol ⁻¹]*	K _d [nM]*	n _{H+}
6.5	-38.7 ± 0.3	163 ± 18	-0.68 ± 0.18
6.7	-39.8 ± 0.4	104 ± 15	-0.47 ± 0.16
7.0	-40.7 ± 0.2	74 ± 7	-0.39 ± 0.04
7.2	-40.4 ± 0.5	85 ± 16	-
7.5	-41.1 ± 0.2	61 ± 6	-0.20 ± 0.03
7.7	-41.5 ± 0.6	53 ± 12	-
8.0	-41.6 ± 0.3	51 ± 7	-0.02 ± 0.03
8.2	-42.0 ± 0.2	44 ± 3	-
8.5	-42.1 ± 0.3	40 ± 5	-0.04 ± 0.09
8.7	-41.6 ± 0.2	52 ± 4	0.01 ± 0.08

Table 2. Thermodynamic parameters for hCK2α-5,6-DBBt interaction determined by ITC. *Weighted averages calculated from data presented in Suppl. Table S1.




Figure 2. pH-dependence of binding of 5,6-DBBt to the hCK2α. ITC-derived K_{diss} values were estimated solely in Bis-Tris Propane buffer (A) or using a set of eleven buffers at each pH chosen according to the pH-dependent buffering properties (B).

TBBt. The hydrophobic effect and halogen bonding can explain the slight difference in binding affinity between 1-CH₃-TBBt and 1-CH₃-5,6-DBBt because the ligand carrying more bromine atoms is much more hydrophobic and possibly forms more halogen bonds. The binding affinity of 1-CH₃-5,6-DBBt was independently estimated by ITC, indicating the K_{diss} of 1.56 ± 0.52 μM (weighted average from Suppl. Table S1).

Both 2-CH₃-derivatives do not stabilize the protein at all tested pH values (ΔT_m does not exceed 0.5 °C). Lack of stabilization indicates that these ligands do not interact with hCK2α. In silico modelling of hCK2α in complex with 2-CH₃-5,6-DBBt (Suppl. Fig. S2C) confirms that the methylation of benzotriazole at N2 introduces steric hindrances and the binding poses of N2-methylated derivatives must differ from those observed for unsubstituted ones.

The pH-dependent binding affinity of 5,6-DBBt monitored with ITC. The binding of 5,6-DBBt to hCK2α was initially studied in the pH range of 6.5 to 8.7 in Bis-Tris Propane buffer using isothermal titration calorimetry (ITC). The resulting thermodynamic parameters are summarized in Table 2 and presented in detail in Suppl. Table S1. The apparent binding affinity to hCK2α varies non-linearly (Fig. 2A), with the putative inflection point roughly reflecting the pK_a for dissociation of the 5,6-DBBt triazole proton (6.93⁶³).




Figure 3. pH dependence of the heat of 5,6-DBBt-hCK2 α binding determined in various buffered solutions characterized by different heats of buffer ionization (A). The negative slope at moderately acidic conditions indicates proton release upon complex formation. Correlation between the estimated number of transferred protons— n_{H^+} —and the pH-dependent dissociation equilibrium of the free 5,6-DBBt (B).

The neutral form of 5,6-DBBt predominating at lower pH binds to hCK2 α visibly weaker than the anionic one at pH 8.7, while the hydrophobic solvation should favor the binding of the neutral ligand. This tendency could be explained by different binding modes of the neutral and anionic forms of the ligand. However, it is most likely associated with binding-induced ligand deprotonation. The thermodynamic contribution of such a process can be described by pH-dependent change of the ligand-binding affinity according to Eq. (1)⁶⁹:

$$K_{\text{diss}} = K_{\text{int}} \cdot \frac{1 + 10^{(pK_a^f - pH)}}{1 + 10^{(pK_a^c - pH)}} \quad (1)$$

where K_{int} is the intrinsic dissociation constant for the anionic form of the ligand, pK_a^f , and pK_a^c are the pK_a values for deprotonation of this ligand in solution and in complex with hCK2 α , respectively. The model was fitted to the experimental K_{diss} values determined at varying pH. pK_a^f was constrained to the experimental value of 6.93⁶³, while the values of pK_a^c and K_{int} were fitted using the experimental data (5.6 ± 0.4 and 44.3 ± 1.3 nM, respectively). The change in the protonation state of the ligand contributes significantly to its binding to hCK2 α . For the neutral form of 5,6-DBBt (i.e., when $10^{(pK_a^c - pH)} \gg 1$) K_{diss} can be, according to Eq. (1), roughly estimated as $K_{\text{int}} \cdot 10^{(pK_a^f - pK_a^c)} \approx 1$ μM , which is close to the experimental value determined for 1-CH₃-5,6-DBBt (1.56 ± 0.52 μM).

The thermodynamic parameters for 5,6-DBBt-hCK2 α binding were determined at seven pH values in the range of 6.5–8.7 in eleven buffered solutions (Suppl. Material), each characterized by the different enthalpy of ionization⁷⁰. We have confirmed the absence of buffer-specific effects since the K_{diss} vs. pH relationship for multiple buffering solutions agrees with that determined solely in the Bis-Tris Propane (Fig. 2B).

Protonation balance upon ligand binding assessed from buffer-dependent ITC-derived heat of binding. In general, any binding associated protonation event affects the apparent enthalpy of ligand binding, ΔH_{bind} , by the individual contribution of ionization enthalpy of the particular buffer, ΔH_i^b , according to the formula:

$$\Delta H_{\text{bind}} = \Delta H_0 + \Delta H_i^b \cdot n_{H^+} \quad (2)$$

where n_{H^+} describes the number of protons transferred from the buffer upon forming the protein–ligand complex⁶⁹.

We have applied Eq. (2) to the ITC data collected at various pH values (6.5, 6.7, 7.0, 7.5, 8.0, 8.5, and 8.7) in eleven different buffers (Fig. 3A). At basic conditions ($\text{pH} \geq 8$), ΔH_{bind} does not depend on ΔH_i^b , clearly proving that the monoanionic form of the ligand, which dominates in solution, also predominates when 5,6-DBBt




Figure 4. Heat of 5,6-DBBt binding to hCK2α determined in various conditions. The surface, representing the model of the binding-induced shift of ligand ionization [Eq. (4)], is colored according to the heat of binding. Each data point, representing an individual titration experiment, is accompanied by a standard error (vertical line) and denoted by the name of the buffer used in the experiment.

binds to the protein. However, the buffer contribution at lower pH becomes significant with negative n_{H^+} values (Table 2). According to the F-test ($F(3,37) = 27.17$, $p < 10^{-11}$), the model with pH-dependent n_{H^+} must be regarded better than that with a universal pH-independent n_{H^+} value. The variation in the apparent number of transferred protons, n_{H^+} , correlates with the pH-dependent dissociation equilibrium of the free 5,6-DBBt (Fig. 3B), unequivocally proving that the observed change of binding affinity with pH must be attributed to the binding-induced deprotonation of the ligand. The data indicate that a proton is released to the buffered solution upon ligand binding at moderately acidic conditions. Therefore, the ligand in the anionic form is bound, even at lower pH.

It is worth emphasizing that the term ΔH_0 in Eq. (2) contains not only the intrinsic binding enthalpy, ΔH_{intr} , but also additional contributions associated with protonation events⁶⁹:

$$\Delta H_0 = \Delta H_{intr} + \overline{H}^f \cdot \Delta H_p^f + \overline{H}^c \cdot \Delta H_p^c \quad (3)$$

where $\overline{H}^f$, ΔH_p^f , and $\overline{H}^c$, ΔH_p^c are the fraction of protons and the enthalpy of ligand protonation in solution and in the complex, respectively. For a single protonation event, the above equation could be rephrased as⁶⁹:

$$\Delta H_{bind} = H_{intr} + (\Delta H_i - \Delta H_{diss}) \cdot \Delta n + \Delta \Delta H_{diss} \cdot \frac{10^{(pK_a^c - pH)}}{1 + 10^{(pK_a^c - pH)}} \quad (4)$$

where $\Delta n = \frac{1}{1 + 10^{(pK_a^f - pH)}} - \frac{1}{1 + 10^{(pK_a^c - pH)}}$ is the net proton transfer upon a binding event, and pK_a^c and pK_a^f are the pK_a values for proton dissociation for the ligand in complex and in solution, respectively. ΔH_i and ΔH_{diss} are the heats of (de)protonation for the buffer and free ligand, and $\Delta \Delta H_{diss}$ is the change of the heat of (de)protonation for the ligand bound to the protein.

Global fitting of the experimentally determined ΔH_{bind} as a function of pH and ΔH_i [Eq. (4)] leads to estimates of all parameters connected with the deprotonation event. A fitted three-dimensional surface relating the experimental ΔH_{bind} to pH and ΔH_i is shown in Fig. 4. The pK_a values estimated from the analysis equal 6.99 ± 0.16 for the free ligand and 6.1 ± 0.3 for the ligand in the complex. Both are close to the values estimated from the K_{diss} data. The intrinsic enthalpy, ΔH_{intr} , is -53.7 ± 0.5 kJ·mol⁻¹, while the enthalpy of protonation in the free state, ΔH_{diss} , is -29 ± 5 kJ·mol⁻¹, and upon binding changes to -21 ± 14 kJ·mol⁻¹ ($\Delta \Delta H_{diss} \sim 8$ kJ·mol⁻¹).

Structure determination. The structures of 5,6-DBBt and TBBt in complex with hCK2α obtained at pH 7.5 were published within a set of eight bromobenzotriazole-hCK2α complexes⁶⁵. In order to provide the structural interpretation of the thermodynamic data, we have now grown crystals of human CK2α in complex with either 5,6-DBBt or TBBt in the pH range of 5.5–9.5. 5,6-DBBt-hCK2α complex crystallized up to pH 8.5,

	hCK2-5,6-DBBt	hCK2-5,6-DBBt	hCK2-5,6-DBBt	hCK2-4,5,6,7-TBBt
pH	5.5	6.5	8.5	8.5
Inhibitor	co-crystallized	co-crystallized	soaked	soaked
Mg ²⁺	4 mM	4 mM	4 mM	4 mM
Data collection				
Space group	<i>P</i> ₄ ₂ ₁ ₂	<i>P</i> ₄ ₂ ₁ ₂	<i>P</i> ₄ ₂ ₁ ₂	<i>P</i> ₄ ₂ ₁ ₂
Unit cell dimensions				
a, b (Å)	127.5	128.5	129.5	127.8
c (Å)	61.0	61.2	60.9	61.2
Wavelength (Å)	0.9117	0.9117	0.9117	0.9117
Beamline	DESY P11	DESY P11	DESY P11	DESY P11
Resolution (Å)	2.55	2.58	2.30	2.27
Lowest shell	(45.1–7.55)	(45.4–7.64)	(45.8–6.84)	(45.2–6.74)
Highest shell	(2.70–2.55)	(2.73–2.58)	(2.44–2.30)	(2.41–2.27)
R _{meas} (%) [*]	30.4 (9.4, 135.9)	31.4 (6.2, 210.5)	11.2 (3.9, 87.3)	11.5 (3.6, 174.9)
CC _{1/2} [*]	99.5 (99.9, 80.3)	99.6 (99.9, 68.6)	99.9 (100, 93.5)	100 (100, 84.5)
I/σI [*]	10.7 (31.7, 2.03)	12.6 (43.4, 1.99)	27.7 (80.2, 4.24) ^{***}	26.1 (88.4, 2.53) ^{***}
Completeness (%) [*]	99.9 (99.3, 99.8)	99.8 (99.3, 99.8)	99.2 (99.5, 99.4)	99.8 (99.5, 99.5)
Multiplicity [*]	26.3 (23.0, 26.9)	26.0 (25.3, 26.4)	25.4 (22.3, 26.1)	26.3 (21.9, 26.5)
Number of reflections	16,932	16,669	23,379	24,013
Refinement				
R _{work}	17.05	17.99	17.91	17.12
R _{free}	23.15	23.44	22.06	20.54
No. atoms ^{**}	3448	3263	3386	3519
Protein	3087	2886	2848	3111
Ligand	11	22	22	26
Other	350	269	385	382
Bond lengths rmsd (Å)	0.007	0.007	0.007	0.007
Bond angles rmsd (°)	1.18	1.17	1.19	1.22
Ramachandran				
Allowed (%)	100	100	100	100
Favored (%)	95.8	96.4	97.3	96.7
Molprobrity clashscore	1	1.0	1.5	0.5
PDB accession code	7QGC	7QGB	7QGD	7QGE

Table 3. Data collection and refinement statistics. Significant values are in bold. The statistics for crystal replicates are presented in Suppl. Table S2. ^{*}Lowest and highest shell in brackets. ^{**}Alternative conformations counted separately. ^{***}Data cut due to ice rings.

whereas TBBt crystals were obtained only at pH 7.5⁶⁵ and 8.5 (Table 3). The electron densities indicate that the ligands are located in the ATP binding pocket of the kinase. 5,6-DBBt adopted a single pose highly similar for all pH values. For TBBt, multiple poses were observed at both pH values, but the weaker ones were less prominent at pH 8.5, possibly due to the lower resolution of the crystals. In some cases, we collected data for several crystals to confirm that the ligand binding poses and the results were internally consistent (Suppl. Table S2 and Suppl. Fig. S3).

The hydrophobic faces of 5,6-DBBt stack on one side against V53 and V66 of the N-terminal lobe and on the other side against M163 and I174 from the C-terminal lobe. The phenyl ring of F113, tilted relative to the benzotriazole ring, may limit the penetration depth of the ligand into the pocket. In the plane of the benzotriazole ring, the ligand position is predominantly determined by the salt bridge between the N2 of 5,6-DBBt and the ε-amino group of K68. The bromine atoms of 5,6-DBBt are pointed roughly towards the mainchain oxygen atoms of E114 and N117 and the sidechain carbonyl oxygen atom of N118. However, in all cases, bromine-oxygen distances are too large for halogen bonding (Suppl. Table S3). The predominance of salt bridge formation over halogen bonding at all pH values is also supported by the composite omit maps and anomalous diffraction data, making it possible to accurately locate the bromo substituents (Suppl. Figs. S3 and S4).

The crystallographic data indicate significant differences between the binding modes of 5,6-DBBt and TBBt. 5,6-DBBt is bound in a single, pH-independent pose, compatible with salt bridge formation of the (anionic) ligand, but not halogen bonding. By contrast, TBBt is bound in multiple poses, some of which feature halogen bonds. The weaker poses of TBBt are not observed at pH 8.5, but it might be due to the weaker diffraction of the crystals. Due to steric constraints, the binding mode of 5,6-DBBt is not anticipated by any of the binding modes of TBBt. Compared to TBBt, 5,6-DBBt is bound more “deeply” in the pocket. TBBt could not bind in this pose




Figure 5. Crystal structures of brominated benzotriazoles in complex with hCK2 α . The structures determined for crystals grown at various pH values have been overlaid. The single binding pose of 5,6-DBBt is consistent across the 5.5–8.5 pH range (A). Two dominant orientations of TBBt are observed at both pH values (7.5 and 8.5) (B, C), weaker binding poses of TBBt are only observed at pH 7.5⁶⁵ (D). Protein carbon atoms are in light blue, and benzotriazole carbon atoms are in green. Bromo substituents and their distances to carbonyl oxygens are in yellow.




Figure 6. Color-coded representation of the differences in the deuteration of hCK2 α due to 5,6-DBBt binding at pH 6.7 and 8.7 (10 s hydrogen deuterium exchange applied).

because bromo substituents in the 4- and 7-positions would clash with F113 and I95. Moreover, the dominant conformation of R47 in the complex with 5,6-DBBt would also preclude the experimentally observed binding mode of TBBt. In the complex with TBBt, R47 gives way, so the bulkier TBBt fits into the pocket (Fig. 5, Suppl. Figs. S3 and S5).

Ligand-induced changes in hydrogen/deuterium exchange monitored by mass spectrometry (HDX-MS). HDX-MS experiments could indirectly reveal the ligand pose in the complex because the internal dynamics of the hinge region is expected to be affected by the ligand location. Hence, we compared the position of 5,6-DBBt in complex with hCK2 α at pH 6.7 and 8.7. At both conditions, the deuterium exchange for the free form of hCK2 α and its complex with 5,6-DBBt was monitored after 10 s exposure to D₂O.

Overall, 5,6-DBBt protected the ATP binding site better at pH 8.7 than at pH 6.7 due to the higher affinity of the ligand at a basic pH (Fig. 6). The highest ligand-induced protection, exceeding 20%, was observed at pH 8.7 for residues R172–E180, covering the DWG motif of the activation loop. No statistically significant protection was seen for this region at lower pH. At pH 8.7, the protection was also seen for regions covering residues V112–V116 and G52–N58 (Fig. 6). The effect can be attributed to a second binding site, which is occupied in

some of the structures of the complex with 5,6-DBt and in complex with TBBt (Suppl. Table S2, Suppl. Fig. S6 and ⁶⁵) and confirmed for 5,6-DBt by MST data⁷¹.

Against the overall better protection of the ATP binding pocket at higher pH due to tighter ligand binding, one fragment (residues N117-L124) corresponding to the hinge region of the kinase was better protected by 5,6-DBt at lower pH (H/D exchange reduced by 10% at pH 6.7, but only by 5% at pH 8.7). This effect is consistent with an expected pH-driven shift in the ligand pose. At higher pH, 5,6-DBt binds closer to K68 (anchored by salt bridges to E81 and D175, shown in stick representation in Fig. 6). As a consequence, it is away from the hinge and provides minimal protection to this region. The data suggest that at lower pH the ligand may move towards the hinge. It could be due to a slight pose change of the majority of ligand molecules in the population. Alternatively, a minor fraction of the ligands may shift more substantially and favor halogen bonding to the hinge over the interaction with K68. The protonation equilibrium is faster than the ligand shift, so at a lower pH, the ligand is statistically closer to the hinge. However, only the dominant pose is visible in the crystal structures.

Ligand binding also induced global changes in internal dynamics/flexibility of hCK2 α . The binding of 5,6-DBt at pH 6.7 slowed down hydrogen–deuterium exchange for numerous residues located in the C-terminal lobe of the GHI subdomain, especially for the CMGC kinase-specific α -GH insert (L249-Q290, Fig. 6). This region seems irrelevant to the structural stability of the C-terminal domain, but it is highly conserved throughout the whole CMGC group and putatively involved in the substrate recognition^{72,73}.

Discussion

Recent studies have suggested that the ligand-binding pose of halogenated benzimidazoles and benzotriazoles in EPKs is determined by a competition between hydrogen bonding/salt bridge formation and halogen bonding^{61,62}. In this tug of war, halogen bonding pulls the ligands towards the hinge region. Conversely, hydrogen bonding/salt bridge formation drags them towards K68 (the lysine from the N-lobe involved in binding of the α - and β -phosphate in the productive complex with the co-substrate ATP), favoring the ligand binding pose further away from the hinge. The outcome of this competition is difficult to predict, in part because the thermodynamic contribution of halogen bonding to intermolecular interaction remains controversial, with free energy estimates for aqueous media ranging from 0.2⁶⁰ up to 7³⁶ kcal/mol. Moreover, the shape and hydrophobicity modulate ligand poses in the kinase pocket.

5,6-DBt with $pK_a = 6.93$ is neutral at low and anionic at high pH. In maize CK2, we observed two 5,6-DBt poses, one with halogen bonding to the hinge and another with salt bridge formation to K68 (5TS8⁷⁴). Assuming that halogen bonds may outcompete a hydrogen bond but not a salt bridge, we reasoned that the binding pose of 5,6-DBt may be pH-controllable. H/D exchange data support the idea. Mainchain amide protons in the hinge region are better protected at low than high pH, as expected if the ligand shifts towards the hinge at low pH. The 5,6-DBt binding is tighter at high than at low pH, suggesting a higher contribution of the interaction with K68 to the ligand binding.

However, except for the H/D exchange data, there is limited support for a pH-dependent ligand shift. The most direct evidence for a pH-independent binding pose of 5,6-DBt away from the hinge comes from the crystallographic data that shows essentially superimposable ligand binding modes backed up by anomalous scattering data. A crystal contact-induced artifact is implausible because the ligand-binding pocket is not close to a crystallographic interface. Instead, the largely pH-independent ligand pose is likely due to perturbations of the pK_a of 5,6-DBt in the ligand-binding pocket.

Global analysis of ITC data collected for 5,6-DBt in various buffers in the pH range of 6.5–8.7 (Fig. 4) unequivocally shows that the apparent pK_a for dissociation of the triazole proton is lowered by almost one unit upon binding to hCK2 α (6.1 vs. 6.93, respectively). Consequently, the inflection point observed for 5,6-DBt in nanoDSF and ITC experiments must be assigned directly to the dissociation of the ligand triazole proton enforced by ligand binding. No such pH dependence is observed in nanoDSF data obtained for non-dissociable neutral ligands substituted with a methyl group at the triazole nitrogen, all of which bind substantially weaker to the target protein. These results might explain the observed apparent discrepancy between HDX-MS and crystallography. It is possible that at pH 6.7 in the HDX experiment, a small fraction of the neutral form of the ligand might be observed; however, it is not substantial enough to be visible in crystallography, even at lower pH. Based on the pK_a , the ligand should be predominantly neutral at the lowest tested pH (5.5), yet we still see the pH-independent pose close to K68. The latter could either indicate that the pH in the crystals varies slightly from the pH in the crystallization buffer or that even a hydrogen bond suffices to outcompete halogen bonding.

To put the data on 5,6-DBt into perspective, we have studied all available structures of benzotriazole resembling compounds in complex with protein kinases (Suppl. Table S4). According to this analysis, ionizable benzotriazole analogues tend to bind close to the lysine, if there are only two halogen substituents, and closer to the hinge, when there are three or four substituents. The non-ionizable analogues, which cannot form a salt bridge, adopt almost universally poses close to the hinge. Hence, it appears that the hydrophobic effect and halogen bonding dominate when there are three or more halogens, or when only a hydrogen bond, but not a salt bridge, would be possible on the side of the lysine. By contrast, the salt bridge dominates in the case of 5,6-DBt with only two halogen substituents.

Summarizing, thermodynamic studies demonstrate that at a pH range of 6.0 to 8.5, 5,6-DBt is mostly or at least partly anionic in complex with hCK2 α due to binding-induced pK_a perturbations from 6.9 in solution down to 6.1 in the complex. Therefore, halogen bonding is outcompeted by salt bridge formation, even at pH below pK_a . Hydrogen deuterium exchange data indicate that the hinge region is better protected at pH 6.7 than 8.7, suggesting that a minor population of 5,6-DBt, not detectable by X-ray crystallography, may shift towards the hinge region, promoting halogen bonding. Despite this subtle effect, ionic interactions predominate over halogen bonding in the hCK2 α -5,6-DBt complex.




Figure 7. Schematic diagrams of the compounds used in the study.

Materials and methods

This manuscript does not involve the use of any animal or human sample/data.

Expression and purification of hCK2 α . The catalytic subunit of human CK2 (hCK2 α) was expressed and purified as described previously³⁵. Protein sample homogeneity was routinely confirmed by gel electrophoresis. Proper folding of hCK2 α was validated with a thermal profile of fluorescence-monitored protein stability prior to calorimetric experiments³⁴.

Ligand synthesis. 5,6-dibromo-1*H*-benzotriazole (5,6-DBBt) and 4,5,6,7-tetrabromo-1*H*-benzotriazole (TBBt) were synthesized according to the previously used methods³⁵.

Methylation of 5,6-dibromo-1*H*-benzotriazole: The solution of 5,6-dibromo-1*H*-benzotriazole (300 mg, 1.08 mmol, 1.0 equiv.) in acetonitrile (5 ml), was mixed with DBU (0.26 ml, 1.73 mmol, 1.6 equiv.) and methyl iodide (0.32 ml, 5.20 mmol, 4.8 equiv.) and stirred at 55 °C for 24 h. The volatiles were then evaporated under reduced pressure, and the resulting oily residue was purified by column chromatography using a toluene/dichloromethane 1:1 v/v mixture, followed by crystallization from nitromethane. The yield of 5,6-dibromo-1-methyl-1*H*-benzotriazole (1-CH₃-5,6-DBBt) was 204 mg (65%, more polar), white solid, m.p. = 208.8–210.8 °C. The yield of 5,6-dibromo-2-methyl-1*H*-benzotriazole (2-CH₃-5,6-DBBt) was 85 mg (27%, less polar), white solid, m.p. = 200.1–201.9 °C.

Methylation of 4,5,6,7-tetrabromo-1*H*-benzotriazole: The solution of 4,5,6,7-tetrabromo-benzotriazole (870 mg, 2.00 mmol, 1.0 equiv.) in acetonitrile (16 ml) was mixed with DBU (0.48 ml, 3.20 mmol, 1.6 equiv.) and methyl iodide (0.64 ml, 9.60 mmol, 4.8 equiv.) and stirred at 55 °C for 24 h. The precipitate was filtered off under reduced pressure and purified by column chromatography using toluene/chloroform 1:1 v/v mixture, followed by crystallization from nitromethane. The yield of 4,5,6,7-tetrabromo-1-methyl-1*H*-benzotriazole (1-CH₃-TBBt) was 314 mg (35%, more polar), white solid, m.p. = 225.0–226.0 °C. The yield of 4,5,6,7-tetrabromo-2-methyl-1*H*-benzotriazole (2-CH₃-TBBt) was 50 mg (11%, less polar), white solid, m.p. = 250.0–253.0 °C. The schematic diagrams of the compounds are presented in Fig. 7.

Crystallization. Crystallization of hCK2 α -bromobenzotriazole complexes was carried out as described previously⁶⁵. The protein concentrated to 4–8 mg/ml in the buffer containing 25 mM Tris–HCl pH 8.5, 0.5 M NaCl, and 5 mM β -mercaptoethanol was mixed with 0.25 M ligand DMSO solution in a 1:24 molar ratio. Crystals were grown from 1:1 mixtures of the protein–ligand solution and crystallization buffers listed in Suppl. Material. No additional cryo-protection was used prior to flash-freezing in liquid nitrogen. Diffraction data were collected at the P11 and P14 beamlines of (EMBL) DESY (Hamburg, Germany) and MX beamline 14.1 of BESSY (Berlin, Germany).

Structure determination. The structure determination was performed as in⁶⁵ for consistency between different pH values. Briefly, the structures were solved by molecular replacement using the structure of hCK2 α (PDB code 3WAR) as the search model⁷⁵. They were rebuilt with ARP/wARP⁷⁶ and refined with REFMAC⁷⁷. The R_{free} reflections were selected in thin resolution shells. The structures determined at pH 7.5 were published

before⁶⁵. The presence and position of the ligands were verified using anomalous difference maps generated with the Fourier transform of the hCK2α structures with the ligands omitted (Suppl. Figs. S3–S6). The ligand constraints were generated with the PRODRG server⁷⁸. Table 3 summarizes data collection and refinement statistics. The atomic coordinates of the final models and the corresponding structure factors have been deposited in the Protein Data Bank (PDB) with the following accession codes: 5,6-DBBt at pH 5.5—7QGC, at pH 6.5—7QGB, at pH 8.5—7QGD, TBBt at pH 8.5—7QGE.

Low-volume differential scanning fluorimetry (nanoDSF). The assay was carried out in 25 mM Bis-Tris Propane, 0.5 M NaCl buffer with constant protein and ligand concentrations of 2.5 μM and 25 μM, respectively. The samples were loaded into nanoDSF Grade Standard Capillaries (NanoTemper Technologies) and analyzed using the Prometheus NT.48 nanoDSF device (NanoTemper Technologies). All experiments were performed and analyzed as described previously⁶⁵.

Isothermal titration calorimetry (ITC). ITC measurements were carried out using MicroCal iTC200 (Malvern). In all experiments, hCK2α samples were transferred to the appropriate buffer using Pierce™ Polyacrylamide Spin Desalting Columns (Thermo Scientific). Stock ligand DMSO solutions were diluted with the appropriate DMSO volume before mixing with the buffer to obtain the required ligand concentration with a final DMSO content of 1%. The experimental setup and the analysis algorithm have already been described in detail⁶⁵, the buffer list is presented in Suppl. Material.

Numeric analysis of nanoDSF and ITC data. Appropriate models were fitted to the experimental data using the Levenberg–Marquardt algorithm implemented in the Origin package (ver. 9.9, www.originlab.com). The standard errors for the derived parameters were estimated according to the Error Propagation formula (<https://www.originlab.com/doc/origin-help/nlfit-theory>).

Hydrogen–deuterium exchange mass spectrometry (HDX-MS). The general experimental procedure was described previously⁷⁹ with the additional sample digestion with 5 μl of protease Type XIII from *Aspergillus saitoi* (30 μg/μl stock) for 30 s on ice before loading onto an immobilized pepsin column. We used 40 μM stock solutions of hCK2α, hCK2α peptides were obtained at pH 8.0, and hydrogen–deuterium exchange experiments were performed for free hCK2α protein and hCK2α-5,6-DBBt complex (tenfold excess of the ligand) at two pH values (6.7 and 8.7).

For 37 hCK2α-derived peptides with extreme HDX protection (indicated in gray in Suppl. Fig. S7), the theoretical percentage of deuteration, D, was calculated by omitting the back-exchange, and the simplified formula $D[\%] = \frac{M_{ex}}{(n_{aa}-1-n_{pro})} \cdot 100\%$ was used instead of the standard one: $D[\%] = \frac{(M_{ex}-M_{ex}^0)}{(M_{ex}^{100}-M_{ex}^0)} \cdot 100\%$

where n_{aa} and n_{pro} are numbers of all amino acids and proline residues in a peptide. M_{ex} , M_{ex}^0 , and M_{ex}^{100} are 10-s, minimal and maximal exchange for a given peptide. Errors were estimated as standard deviations of three independent experiments.

Data availability

The coordinates and structure factors have been deposited to the Protein Data Bank (<https://www.rcsb.org>) under accession numbers: 7QGC (<https://www.rcsb.org/structure/7QGC>), 7QGB (<https://www.rcsb.org/structure/7QGB>), 7QGD (<https://www.rcsb.org/structure/7QGD>), 7QGE (<https://www.rcsb.org/structure/7QGE>). All other datasets generated and/or analyzed within this study are available from the corresponding author on a reasonable request.

Received: 10 June 2022; Accepted: 2 November 2022

Published online: 08 November 2022

References

- Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. *Science* **298**, 1912–1934. <https://doi.org/10.1126/science.1075762> (2002).
- Pinna, L. A. The raison d'être of constitutively active protein kinases: The lesson of CK2. *Acc. Chem. Res.* **36**, 378–384. <https://doi.org/10.1021/ar020164f> (2003).
- Sarno, S., Ghisellini, P. & Pinna, L. A. Unique activation mechanism of protein kinase CK2: The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. *J. Biol. Chem.* **277**, 22509–22514. <https://doi.org/10.1074/jbc.M200486200> (2002).
- Gietz, R. D., Graham, K. C. & Litchfield, D. W. Interactions between the subunits of casein kinase II. *J. Biol. Chem.* **270**, 13017–13021 (1995).
- Lou, D. Y. *et al.* The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. *Mol. Cell. Biol.* **28**, 131–139. <https://doi.org/10.1128/MCB.01119-07> (2008).
- Xu, X., Toselli, P. A., Russell, L. D. & Seldin, D. C. Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. *Nat. Genet.* **23**, 118–121. <https://doi.org/10.1038/12729> (1999).
- Meggio, F., Marin, O. & Pinna, L. A. Substrate specificity of protein kinase CK2. *Cell. Mol. Biol. Res.* **40**, 401–409 (1994).
- Meggio, F. & Pinna, L. A. One-thousand-and-one substrates of protein kinase CK2?. *FASEB J.* **17**, 349–368. <https://doi.org/10.1096/fj.02-0473rev> (2003).
- Guerra, B. & Issinger, O. G. Protein kinase CK2 in human diseases. *Curr. Med. Chem.* **15**, 1870–1886 (2008).
- Trembley, J. H., Wang, G., Unger, G., Slaton, J. & Ahmed, K. Protein kinase CK2 in health and disease. *Cell. Mol. Life Sci.* **66**, 1858–1867 (2009).
- Ruzzene, M. & Pinna, L. A. Addiction to protein kinase CK2: A common denominator of diverse cancer cells?. *BBA Proteins Proteom.* **1804**, 499–504. <https://doi.org/10.1016/j.bbapap.2009.07.018> (2010).

12. Chua, M. M. J. *et al.* CK2 in cancer: Cellular and biochemical mechanisms and potential therapeutic target. *Pharmaceuticals* **10**, 18 (2017).
13. Trembley, J. H., Wu, J., Unger, G. M., Kren, B. T. & Ahmed, K. CK2 suppression of apoptosis and Its implication in cancer biology and therapy. In *Protein kinase CK2* (ed L. A. Pinna) Ch. **12**, 319–343 (Wiley, 2013).
14. Dominguez, I., Sonenshein, G. & Seldin, D. Protein kinase CK2 in health and disease. *Cell. Mol. Life Sci.* **66**, 1850–1857 (2009).
15. Seldin, D. C. & Landesman-Bollag, E. The Oncogenic Potential of CK2. in *Protein Kinase CK2* (ed L. A. Pinna) Ch. **10**, 293–304 (Wiley, 2013).
16. BenaventAcero, F. *et al.* CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. *Lung Cancer* **107**, 14–21. <https://doi.org/10.1016/j.lungcan.2016.05.026> (2016).
17. Perea, S. E., Baladron, I., Valenzuela, C. & Perera, Y. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. *Semin. Oncol.* **45**, 58–67. <https://doi.org/10.1053/j.seminoncol.2018.04.006> (2018).
18. Perea, S. E. *et al.* Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). *Cancer Res.* **64**, 7127–7129. <https://doi.org/10.1158/0008-5472.can-04-2086> (2004).
19. Perera, Y. *et al.* Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. *Mol. Cancer Ther.* **8**, 1189–1196. <https://doi.org/10.1158/1535-7163.mct-08-1056> (2009).
20. Solares, A. M. *et al.* Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intravenously at four dose levels in patients with cervical malignancies. *BMC Cancer* **9**, 146. <https://doi.org/10.1186/1471-2407-9-146> (2009).
21. Ferguson, A. D. *et al.* Structural basis of CX-4945 binding to human protein kinase CK2. *FEBS Lett.* **585**, 104–110. <https://doi.org/10.1016/j.febslet.2010.11.019> (2011).
22. Marschke, R. F. *et al.* Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. *J. Clin. Oncol.* **29**, 3087–3087 (2011).
23. Siddiqui-Jain, A. *et al.* CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. *Cancer Res.* **70**, 10288 (2010).
24. Bouhaddou, M. *et al.* The global phosphorylation landscape of SARS-CoV-2 infection. *Cell* **182**, 685–712.e619 (2020).
25. Borgo, C., D'Amore, C., Sarno, S., Salvi, M. & Ruzzene, M. Protein kinase CK2: a potential therapeutic target for diverse human diseases. *Sig. Transduct. Target. Ther.* **6**, 183 (2021).
26. Zandomeni, R., Zandomeni, M. C., Shugar, D. & Weinmann, R. Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. *J. Biol. Chem.* **261**, 3414–3419 (1986).
27. Pagano, M. A. *et al.* 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: A novel powerful and selective inhibitor of protein kinase CK2. *Biochem. Biophys. Res. Commun.* **321**, 1040–1044. <https://doi.org/10.1016/j.bbrc.2004.07.067> (2004).
28. Gianoncelli, A. *et al.* Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. *Biorg. Med. Chem.* **17**, 7281–7289. <https://doi.org/10.1016/j.bmc.2009.08.047> (2009).
29. Łukowska-Chojnacka, E., Wińska, P., Wielechowska, M., Poprzeczko, M. & Bretner, M. Synthesis of novel polybrominated benzimidazole derivatives—potential CK2 inhibitors with anticancer and proapoptotic activity. *Biorg. Med. Chem.* **24**, 735–741. <https://doi.org/10.1016/j.bmc.2015.12.041> (2016).
30. Swider, R. *et al.* Synthesis, biological activity and structural study of new benzotriazole-based protein kinase CK2 inhibitors. *RSC Adv.* **5**, 72482–72494 (2015).
31. Szyszka, R., Grankowski, N., Felczak, K. & Shugar, D. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from *Saccharomyces cerevisiae* and other sources. *Biochem. Biophys. Res. Commun.* **208**, 418–424. <https://doi.org/10.1006/bbrc.1995.1354> (1995).
32. Kasperowicz, S. *et al.* A competition between hydrophobic and electrostatic interactions in protein–ligand systems: Binding of heterogeneously halogenated benzotriazoles by the catalytic subunit of human protein kinase CK2. *IUBMB Life* **72**, 1211–1219. <https://doi.org/10.1002/iub.2271> (2020).
33. Marzec, E., Poznański, J. & Paprocki, D. Thermodynamic contribution of iodine atom to the binding of heterogeneously polyhalogenated benzotriazoles by the catalytic subunit of human protein kinase CK2. *IUBMB Life* **72**, 1203–1210. <https://doi.org/10.1002/iub.2257> (2020).
34. Winiewska, M. *et al.* Thermodynamic parameters for binding of some halogenated inhibitors of human protein kinase CK2. *Biochem. Biophys. Res. Commun.* **456**, 282–287 (2015).
35. Winiewska, M., Kucinska, K., Makowska, M., Poznanski, J. & Shugar, D. Thermodynamics parameters for binding of halogenated benzotriazole inhibitors of human protein kinase CK2 alpha. *BBA Proteins Proteom.* **1854**, 1708–1717. <https://doi.org/10.1016/j.bbapap.2015.04.004> (2015).
36. Voth, A. R., Hays, F. A. & Ho, P. S. Directing macromolecular conformation through halogen bonds. *Proc. Natl. Acad. Sci. USA* **104**, 6188–6193. <https://doi.org/10.1073/pnas.0610531104> (2007).
37. Voth, A. R., Khoo, P., Oishi, K. & Ho, P. S. Halogen bonds as orthogonal molecular interactions to hydrogen bonds. *Nat. Chem.* **1**, 74–79. <https://doi.org/10.1038/nchem.112> (2009).
38. Zhou, P., Huang, J. & Tian, F. Specific noncovalent interactions at protein–ligand interface: Implications for rational drug design. *Curr. Med. Chem.* **19**, 226–238 (2012).
39. Poznanski, J. & Shugar, D. Halogen bonding at the ATP binding site of protein kinases: Preferred geometry and topology of ligand binding. *Biochim. Biophys. Acta Proteins Proteom.* **1834**, 1381–1386. <https://doi.org/10.1016/j.bbapap.2013.01.026> (2013).
40. Poznanski, J., Winiewska, M., Czapinska, H., Poznanska, A. & Shugar, D. Halogen bonds involved in binding of halogenated ligands by protein kinases. *Acta Biochim. Pol.* **63**, 203–214. https://doi.org/10.18388/abp.2015_1106 (2016).
41. Eckenhoff, R. G. & Johansson, J. S. Molecular interactions between inhaled anesthetics and proteins. *Pharmacol. Rev.* **49**, 343–367 (1997).
42. Liu, R. Y., Loll, P. J. & Eckenhoff, R. G. Structural basis for high-affinity volatile anesthetic binding in a natural 4-helix bundle protein. *FASEB J.* **19**, 567–576. <https://doi.org/10.1096/fj.04-3171com> (2005).
43. Voth, A. R. & Ho, P. S. The role of halogen bonding in inhibitor recognition and binding by protein kinases. *Curr. Top. Med. Chem.* **7**, 1336–1348 (2007).
44. Memic, A. & Spaller, M. R. How do halogen substituents contribute to protein-binding interactions? A thermodynamic study of peptide ligands with diverse aryl halides. *ChemBioChem* **9**, 2793–2795. <https://doi.org/10.1002/cbic.200800572> (2008).
45. Kraut, D. A., Churchill, M. J., Dawson, P. E. & Herschlag, D. Evaluating the potential for halogen bonding in the oxyanion hole of ketosteroid isomerase using unnatural amino acid mutagenesis. *ACS Chem. Biol.* **4**, 269–273. <https://doi.org/10.1021/cb900016q> (2009).
46. Zou, W. S., Han, J. & Jin, W. J. Concentration-dependent Br...O halogen bonding between carbon tetrabromide and oxygen-containing organic solvents. *J. Phys. Chem. A* **113**, 10125–10132. <https://doi.org/10.1021/jp905914q> (2009).
47. Carter, M. & Ho, P. S. Assaying the energies of biological halogen bonds. *Cryst. Growth Des.* **11**, 5087–5095. <https://doi.org/10.1021/cg200991v> (2011).
48. Hardegger, L. A. *et al.* Systematic investigation of halogen bonding in protein–ligand interactions. *Angew. Chem. Int. Ed.* **50**, 314–318. <https://doi.org/10.1002/anie.201006781> (2011).

49. Aakeroey, C. B., Fasulo, M., Schultheiss, N., Desper, J. & Moore, C. Structural competition between hydrogen bonds and halogen bonds. *J. Am. Chem. Soc.* **129**, 13772. <https://doi.org/10.1021/ja073201c> (2007).
50. Aakeroey, C. B., Panikkattu, S., Chopade, P. D. & Desper, J. Competing hydrogen-bond and halogen-bond donors in crystal engineering. *CrystEngComm* **15**, 3125–3136. <https://doi.org/10.1039/c2ce26747k> (2013).
51. Poznanski, J., Poznanska, A. & Shugar, D. A protein data bank survey reveals shortening of intermolecular hydrogen bonds in ligand-protein complexes when a halogenated ligand is an H-bond donor. *PLoS ONE* <https://doi.org/10.1371/journal.pone.0099984> (2014).
52. Shinada, N. K., de Brevern, A. G. & Schmidtke, P. Halogens in protein-ligand binding mechanism: A structural perspective. *J. Med. Chem.* **62**, 9341–9356. <https://doi.org/10.1021/acs.jmedchem.8b01453> (2019).
53. Bogado, M. I. L. *et al.* Targeting protein pockets with halogen bonds: The role of the halogen environment. *J. Chem. Inf. Model.* <https://doi.org/10.1021/acs.jcim.2c00475> (2020).
54. Jena, S. *et al.* Noncovalent interactions in proteins and nucleic acids: Beyond hydrogen bonding and pi-stacking. *Chem. Soc. Rev.* **51**, 4261–4286. <https://doi.org/10.1039/d2cs00133k> (2022).
55. Frontera, A. & Bauza, A. Biological halogen bonds in protein-ligand complexes: A combined QTAIM and NCIPLOT study in four representative cases. *Org. Biomol. Chem.* **19**, 6858–6864. <https://doi.org/10.1039/d1ob01212f> (2021).
56. Frontera, A. & Bauza, A. Halogen bonds in protein nucleic acid recognition. *J. Chem. Theor. Comput.* **16**, 4744–4752. <https://doi.org/10.1021/acs.jctc.0c00431> (2020).
57. Kuhn, B., Gilberg, E., Taylor, R., Cole, J. & Korb, O. How significant are unusual protein-ligand interactions? Insights from database mining. *J. Med. Chem.* **62**, 10441–10455. <https://doi.org/10.1021/acs.jmedchem.9b01545> (2019).
58. Huber, S. M., Scanlon, J. D., Jimenez-Izal, E., Ugalde, J. M. & Infante, I. On the directionality of halogen bonding. *Phys. Chem. Chem. Phys.* **15**, 10350–10357. <https://doi.org/10.1039/c3cp50892g> (2013).
59. Sutar, R. L. & Huber, S. M. Catalysis of organic reactions through halogen bonding. *ACS Catal.* **9**, 9622–9639. <https://doi.org/10.1021/acscatal.9b02894> (2019).
60. Sarwar, M. G., Dragisic, B., Salsberg, L. J., Gouliaras, C. & Taylor, M. S. Thermodynamics of halogen bonding in solution: Substituent, structural, and solvent effects. *J. Am. Chem. Soc.* **132**, 1646–1653. <https://doi.org/10.1021/ja9086352> (2010).
61. Battistutta, R., De Moliner, E., Sarno, S., Zanotti, G. & Pinna, L. A. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. *Protein Sci.* **10**, 2200–2206. <https://doi.org/10.1110/ps.19601> (2001).
62. Battistutta, R. *et al.* The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. *ChemBioChem* **8**, 1804–1809. <https://doi.org/10.1002/cbic.200700307> (2007).
63. Wasik, R., Winska, P., Poznanski, J. & Shugar, D. Synthesis and physico-chemical properties in aqueous medium of all possible isomeric brom analogues of benzo-1H-triazole, potential inhibitors of protein kinases. *J. Phys. Chem. B* **116**, 7259–7268. <https://doi.org/10.1021/jp301561x> (2012).
64. Wasik, R., Lebska, M., Felczak, K., Poznanski, J. & Shugar, D. Relative role of halogen bonds and hydrophobic interactions in inhibition of human protein kinase CK2 alpha by tetrabromobenzotriazole and some C(5)-substituted analogues. *J. Phys. Chem. B* **114**, 10601–10611. <https://doi.org/10.1021/jp102848y> (2010).
65. Czapinska, H. *et al.* Halogen atoms in the protein-ligand system: Structural and thermodynamic studies of the binding of bromobenzotriazoles by the catalytic subunit of human protein kinase CK2. *J. Phys. Chem. B* **125**, 2491–2503. <https://doi.org/10.1021/acs.jpbc.0c10264> (2021).
66. Bischoff, N. *et al.* Structure of the human protein kinase CK2 catalytic subunit CK2α' and interaction thermodynamics with the regulatory subunit CK2β. *J. Phys. Chem. B* **407**, 1–12 (2011).
67. Lindenblatt, D. *et al.* Molecular plasticity of crystalline CK2α' leads to KN2, a bivalent inhibitor of protein kinase CK2 with extraordinary selectivity. *J. Med. Chem.* **65**, 1302–1312 (2021).
68. Lindenblatt, D. *et al.* Diacritic binding of an indenoindole inhibitor by CK2α paralogs explored by a reliable path to atomic resolution CK2α' structures. *ACS Omega* **4**, 5471–5478 (2019).
69. Baker, B. M. & Murphy, K. P. Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry. *Biophys. J.* **71**, 2049–2055. [https://doi.org/10.1016/s0006-3495\(96\)79403-1](https://doi.org/10.1016/s0006-3495(96)79403-1) (1996).
70. Goldberg, R. N., Kishore, N. & Lennen, R. M. Thermodynamic quantities for the ionization reactions of buffers. *J. Phys. Chem. Ref. Data* **31**, 231–370 (2002).
71. Winiewska, M., Bugajska, E. & Poznanski, J. ITC-derived binding affinity may be biased due to titrant (nano)-aggregation: Binding of halogenated benzotriazoles to the catalytic domain of human protein kinase CK2. *PLoS ONE* **12**, e0173260 (2017).
72. Kannan, N. & Neuwald, A. F. Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2α. *Protein Sci.* **13**, 2059–2077 (2004).
73. Niefind, K., Raaf, J. & Issinger, O. G. Protein kinase CK2: From structures to insights. *Cell. Mol. Life Sci.* **66**, 1800–1816. <https://doi.org/10.1007/s00018-009-9149-8> (2009).
74. Szymaniec-Rutkowska, A. *et al.* Does the partial molar volume of a solute reflect the free energy of hydrophobic solvation? *J. Mol. Liq.* **293**, 111527. <https://doi.org/10.1016/j.molliq.2019.111527> (2019).
75. Kinoshita, T. *et al.* Crystal structure of human CK2 alpha at 1.06 angstrom resolution. *J. Synchrotron Radiat.* **20**, 974–979. <https://doi.org/10.1107/S0909049513020785> (2013).
76. Langer, G., Cohen, S. X., Lamzin, V. S. & Perrakis, A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. *Nat. Protoc.* **3**, 1171–1179. <https://doi.org/10.1038/nprot.2008.91> (2008).
77. Murshudov, G. N. *et al.* REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr. D* **67**, 355–367. <https://doi.org/10.1107/S0907444911001314> (2011).
78. Schüttelkopf, A. W. & van Aalten, D. M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr. D* **60**, 1355–1363. <https://doi.org/10.1107/S0907444904011679> (2004).
79. Premchandrar, A. *et al.* Structural dynamics of the vimentin coiled-coil contact regions involved in filament assembly as revealed by hydrogen-deuterium exchange. *J. Biol. Chem.* **291**, 24931–24950. <https://doi.org/10.1074/jbc.M116.748145> (2016).

Acknowledgements

This work was supported by the Polish National Science Center Grant 2017/25/B/ST4/01613 (JP). Synchrotron data collections were partly funded by the Seventh Framework Program of the European Community (FP7/2007–2013) under the BioStruct-X Grant agreement (N° 283570). Data for this project were collected at the P11 and P14 beamlines of (EMBL) DESY (Hamburg, Germany) and MX 14.1 beamline of BESSY (Berlin, Germany). We are grateful for beamline access and assistance during data collection.

Author contributions

Conceived and designed the experiments: M.W.S. and J.P. M.W.S. expressed the protein and performed all thermodynamic studies. M.W.S. and M.K.D. performed HDX-MS experiments. Analyzed thermodynamic data: M.W.S. and J.P. K.M. performed all syntheses. A.F. conducted crystallization. H.C. and A.F. solved and refined

crystal structures. Analyzed the structures and interpreted data: H.C. and M.B. J.P. designed and supervised the project. Wrote the paper: M.W.S., M.B., H.C., M.K.D., and J.P. All authors have reviewed and approved the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-23611-0>.

Correspondence and requests for materials should be addressed to M.W.-S. or J.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022